Everest Organics Ltd is Rated Strong Sell

Current Rating Overview

MarketsMOJO’s Strong Sell rating for Everest Organics Ltd indicates a cautious stance for investors, signalling that the stock currently exhibits significant risks and challenges. This rating was assigned on 16 March 2026, following a decline in the company’s overall Mojo Score from 31 to 29. The Strong Sell grade suggests that investors should consider avoiding new positions or potentially reducing exposure, given the prevailing fundamentals and market conditions.

How Everest Organics Looks Today: Key Fundamentals

As of 29 March 2026, Everest Organics remains a microcap player within the Pharmaceuticals & Biotechnology sector. The company’s financial health and operational metrics present a mixed picture, which underpins the current rating.

The Quality Grade is assessed as below average, reflecting concerns about the company’s long-term fundamental strength. Specifically, Everest Organics has experienced a negative compound annual growth rate (CAGR) of -12.16% in operating profits over the past five years. This contraction in profitability signals challenges in sustaining growth and operational efficiency.

Financially, the company shows a positive grade, indicating some resilience in recent financial trends. However, this is tempered by a high Debt to EBITDA ratio of 6.46 times, which points to a significant debt burden relative to earnings. Such leverage raises questions about the company’s ability to service its debt obligations comfortably, especially in a volatile market environment.

Return on Equity (ROE) averages at 5.58%, which is relatively low and suggests limited profitability generated from shareholders’ funds. This modest return highlights the company’s struggle to deliver strong value to investors through equity capital.

Valuation and Technical Assessment

From a valuation perspective, Everest Organics is currently rated as attractive. This implies that the stock price may be undervalued relative to its earnings potential or asset base, potentially offering a value opportunity for risk-tolerant investors. However, valuation alone is insufficient to offset the broader concerns reflected in other parameters.

Technically, the stock is graded bearish, indicating downward momentum in price trends. This is corroborated by recent stock returns, which show a sharp decline over multiple time frames. As of 29 March 2026, Everest Organics has delivered a 1-day gain of 2.44%, but this short-term uptick contrasts with longer-term losses: -18.37% over one week, -35.85% over one month, and a steep -49.23% over three months. Year-to-date, the stock has fallen by 54.00%, and over the past year, it has declined by 6.94%. These figures reflect sustained selling pressure and investor caution.

Stock Returns and Market Sentiment

The recent price action and returns data underscore the challenges facing Everest Organics. Despite a minor rebound on the last trading day, the overall trend remains negative, reflecting weak investor confidence. The combination of below-average quality, high leverage, and bearish technicals outweighs the attractive valuation, leading to the Strong Sell recommendation.

What This Rating Means for Investors

For investors, the Strong Sell rating serves as a warning to exercise prudence. It suggests that the stock is currently exposed to significant downside risks, and the company’s fundamentals do not support a positive outlook in the near term. While the valuation may appear tempting, the underlying financial and operational weaknesses, coupled with negative price momentum, advise caution.

Investors should closely monitor Everest Organics’ financial health, particularly its debt servicing capacity and profitability trends, before considering any investment. Additionally, the bearish technical signals imply that the stock may continue to face downward pressure, making it less suitable for those seeking stable or growth-oriented investments.

Sector Context and Market Position

Operating within the Pharmaceuticals & Biotechnology sector, Everest Organics faces intense competition and regulatory challenges. The sector often demands strong innovation pipelines and robust financial management to sustain growth. Everest Organics’ current metrics suggest it is struggling to keep pace with sector peers, which may further weigh on its market valuation and investor sentiment.

Summary of Key Metrics as of 29 March 2026

To recap, Everest Organics Ltd’s current standing is characterised by:

• Mojo Score of 29.0, reflecting a Strong Sell grade
• Below average Quality Grade, with a -12.16% CAGR in operating profits over five years
• Attractive Valuation Grade, indicating potential undervaluation
• Bearish Technical Grade, with significant negative returns over recent months
• Positive Financial Grade, but tempered by a high Debt to EBITDA ratio of 6.46 times
• Low Return on Equity averaging 5.58%

These factors collectively justify the current Strong Sell rating and highlight the risks involved in holding or acquiring this stock at present.

Investor Takeaway

Investors should approach Everest Organics with caution, recognising that the company’s financial and technical indicators suggest ongoing challenges. While the valuation may attract some speculative interest, the overall risk profile remains elevated. Monitoring future earnings reports, debt management, and sector developments will be crucial for reassessing the stock’s potential.

Conclusion

Everest Organics Ltd’s Strong Sell rating by MarketsMOJO, last updated on 16 March 2026, reflects a comprehensive evaluation of its current financial health, valuation, and market trends as of 29 March 2026. The company’s below-average quality, high leverage, and bearish technical outlook outweigh the attractive valuation, signalling caution for investors. This rating serves as a guide for market participants to carefully consider the risks before engaging with this stock.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today